title: Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast?
authors.affiliation: King's College London and Guy's and St Thomas's NHS Foundation Trust, London, UK.
authors.forename: Arnie
authors.initials: A
authors.lastname: Purushotham
authors.forename: Sarah
authors.initials: S
authors.lastname: Pinder
authors.forename: Massi
authors.initials: M
authors.lastname: Cariati
authors.forename: Mark
authors.initials: M
authors.lastname: Harries
authors.forename: Aron
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D018275:Carcinoma, Lobular / Q000188:drug therapy*; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*
chemical_list: D004967:Estrogens; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen